Quantbot Technologies LP lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 97.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,070 shares of the medical equipment provider’s stock after purchasing an additional 3,491 shares during the quarter. Quantbot Technologies LP’s holdings in Hologic were worth $320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Commonwealth Bank of Australia lifted its holdings in shares of Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 600 shares in the last quarter. Miles Capital Inc. purchased a new stake in shares of Hologic during the first quarter valued at $206,000. Beck Mack & Oliver LLC purchased a new stake in shares of Hologic during the second quarter valued at $209,000. Stratos Wealth Partners LTD. purchased a new stake in shares of Hologic during the first quarter valued at $210,000. Finally, Notis McConarty Edward purchased a new stake in shares of Hologic during the second quarter valued at $213,000. Hedge funds and other institutional investors own 96.38% of the company’s stock.

Hologic, Inc. (NASDAQ:HOLX) opened at 37.02 on Tuesday. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The stock has a market cap of $10.38 billion, a PE ratio of 13.79 and a beta of 0.91. The stock’s 50 day moving average is $37.82 and its 200 day moving average is $42.23.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.51 EPS. Analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/hologic-inc-holx-stake-lifted-by-quantbot-technologies-lp/1604882.html.

HOLX has been the subject of several research analyst reports. Deutsche Bank AG reduced their price objective on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) cut shares of Hologic from a “conviction-buy” rating to a “buy” rating and lowered their target price for the company from $48.00 to $47.00 in a research note on Thursday, August 3rd. Needham & Company LLC restated a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. BidaskClub downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price target on shares of Hologic in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $48.43.

In related news, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the transaction, the director now directly owns 23,810 shares in the company, valued at $955,257.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence M. Levy sold 7,139 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The disclosure for this sale can be found here. Insiders sold 18,745 shares of company stock worth $768,189 in the last quarter. Company insiders own 0.79% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.